Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024
Authors | |
---|---|
Year of publication | 2024 |
Type | Article in Periodical |
Magazine / Source | Influenza and Other Respiratory Viruses |
MU Faculty or unit | |
Citation | |
Web | https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13360?src=getftr |
Doi | http://dx.doi.org/10.1111./irv.13360 |
Keywords | COVID-19 XBB1.5 vaccine; Europe; SARS-CoV- 2 hospitalisation; vaccine effectiveness |
Description | We conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 amongadult patients aged ? 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of theeffectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS- CoV-2 hospitalisation. Vaccineeffectiveness was 49% overall, ranging between 69% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, withVE > 70% in older adults (? 65 years) up to 1 month post vaccination. |